Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system

Diabetes Research and Clinical Practice

Volumn 76, Issue 1, 2007, Pages 30-36

  Wang, Xian Ling ^a   Lu, Ju Ming ^a   Pan, Chang Yu ^a   Mu, Yi Ming ^a   Dou, Jing Tao ^a   Ba, Jian Ming ^a   Wang, Xuemin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Continuous glucose monitoring system; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

GLIPIZIDE; GLUCOSE; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FASTING; FEMALE; GLIPIZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; TREATMENT OUTCOME;

EID: 33846895450     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.08.005     Document Type: Article

References (18)

1. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur. J. Clin. Invest. 34 (2004) 410-416
2. Dunn C.J., Plosker G.L., Keating G.M., McKeage K., and Scott L.J. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 63 (2003) 1743-1778
3. Schaepelynck-Belicar P., Vague P., Simonin G., and Lassmann-Vague V. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diab. Metab. 29 (2003) 608-612
4. Kaufman F.R., Gibson L.C., Halvorson M., Carpenter S., Fisher L.K., and Pitukcheewanont P. A pilot study of the continuous glucose monitoring system. Diab. Care 24 (2001) 2030-2034
5. Haak T., Tiengo A., Draeger E., Suntum M., and Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diab. Obes. Metab. 7 (2005) 56-64
6. Fiallo-Scharer R., and Diabetes Research in Children Network Study Group. Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J. Clin. Endocrinol. Metab. 90 (2005) 3387-3391
7. Ludvigsson J., and Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 111 5 Pt 1 (2003) 933-938
8. The Diabetes Research in Children Study Group (DIRECNET). Accuracy of the GlucoWatch G2 Biographer and the continuous glucose monitoring system during hypoglycemia. Diab. Care 27 (2004) 722-726
9. Wang X.L., Lu J.M., and Pan C.Y. Study on preliminary performance of continuous glucose monitoring system in diabetic patients. Cad. J. PLA PostgradMed. Sch. 26 (2005) 63-65 (in Chinese)
10. Kessler L., Passemard R., Oberholzer J., Benhamou P.Y., Bucher P., Toso C., et al. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diab. Care 25 (2002) 2256-2262
11. Owens D.R., Coates P.A., Luzio S.D., Tinbergen J.P., and Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diab. Care 23 (2000) 813-819
12. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diab. Care 26 (2003) 3080-3086
13. Garg S.K., Gottlieb P.A., Hisatomi M.E., D'Souza A., Walker A.J., Izuora K.E., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diab. Res. Clin. Pract. 66 (2004) 49-56
14. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diab. Med. 20 (2003) 545-551
15. Alemzadeh R., Berhe T., and Wyatt D.T. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 115 (2005) 1320-1324
16. Hamann A., Matthaei S., Rosak C., and Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diab. Care 26 (2003) 1738-1744
17. Rosenstock J., Dailey G., Massi-Benedetti M., Fritsche A., Lin Z., and Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diab. Care 28 (2005) 950-955
18. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts10-year survival of type 2 diabetic patients. Diab. Care 23 (2000) 50-54